玻璃体腔注射t-PA和SF_6治疗外伤性黄斑部视网膜下出血的临床研究

INTRAVITREOUS INJECTION OF t-PA AND GAS OF SF_6 TO TREAT TRAUMATIC RETINAL SUBMACULAR HEMORRHAGE

目的研究组织型纤维蛋白溶解酶原激活剂(tissue plasminogen activator,t-PA)和六氟化硫(sulfurhexafluoride,SF_6)玻璃体腔内注射治疗外伤性黄斑部视网膜下出血的临床效果。方法外伤性黄斑部视网膜下出血患者50例50眼,随机分为2组,A组,t-PA和SF_6治疗组;B组,空白对照组。t-PA和SF_6注射量分别为25～50 μg(0.1 mL)和0.5 mL SF_6。结果治疗后10 d,治疗组和对照组相比较出血吸收差异有统计学意义(P<0.05);治疗后1、3个月,2组出血吸收差异有统计学意义(P<0.01)。治疗前、后裸眼视力比较治疗组差异有统计学意义(P<0.05,P<0.01)。末见并发症。结论 t-PA联合SF。玻璃体内注射治疗黄斑部视网膜下出血是一种简便、安全、有效的方法。

Objective To explore the clinical effects of injection of tissue plasminogen activator（t-PA） and gas of sulfur hexafluoride （SF6） to treat traumatic retinal submacular hemorrhage. Methods Fifty eyes with traumatic retinal submacular hemorrhage were randomly divided into Group A treated with t-PA and SF6 and Group B （the control group）. The injection doses of t-PA and SF6 were 25-50 μg （0.1 mL）and 0.5 mL respectively. Results There were statistical difference between Group A and Group B in the absorption of hemorrhage after 10 days of treatment （ P〈0.05）. And the difference were significant on one and three months after treament（ P 〈0.01）. Group A got obvious improvement in visual acuity after treatment （ P 〈0.01） and no complications occurred. Conclusion Intravitreous injection of t-PA and SF6 can be used to treat traumatic retinal submacular hemorrhage effectively.